0
0
Menopause, a natural phase in a woman’s life marked by the end of menstrual cycles, frequently brings distressing symptoms such as hot flashes and night sweats. In a landmark advancement, a new non-hormonal pill called elinzanetant has been shown to reduce these vasomotor symptoms by up to 73%, offering a promising alternative for women who cannot or prefer not to undergo hormone replacement therapy (HRT).
What Happened and Where
This breakthrough comes from the large international OASIS-3 clinical trial involving over 600 postmenopausal women aged 40 to 65, conducted across 83 sites in North America and Europe. The participants received either 120 mg of elinzanetant daily or a placebo for 52 weeks. By week 12, women taking the drug experienced a 73% reduction in the frequency and severity of hot flashes and night sweats compared to placebo, results published in JAMA Internal Medicine confirmed in 2025.
How the Pill Works
Elinzanetant is a dual neurokinin-1 and neurokinin-3 receptor antagonist. These neurokinins are molecules involved in regulating the brain’s thermoregulatory center that controls body temperature. During menopause, declining estrogen levels disrupt normal signaling, leading to increased neurokinin activity that triggers hot flashes. By blocking these receptors, elinzanetant stabilizes this brain activity, reducing vasomotor symptoms without using hormones.
Dr. JoAnn V. Pinkerton, director of midlife health at UVA Health and emeritus executive director of the North American Menopause Society, underscored the significance: “For those dealing with moderate to severe vasomotor symptoms due to menopause, especially women who cannot or choose not to undergo hormone therapy, elinzanetant offers a new, effective option to significantly improve daily quality of life.”
Background and Context
Hot flashes, characterized by sudden heat surges, sweating, and flushing, affect nearly 75% of menopausal women worldwide. Traditional treatment often involves hormone replacement therapy, which replenishes estrogen but carries risks including cardiovascular events and hormone-dependent cancers, making it unsuitable for many.
Non-hormonal alternatives have historically included antidepressants, anticonvulsants, and blood pressure medications, but many offer only modest relief and can cause side effects. The approval of elinzanetant—marketed under names like Veozah (fezolinetant)—marks a first specifically targeted, effective non-hormonal pharmacologic therapy for vasomotor symptoms.
As noted in the British Menopause Society’s recent consensus, while no non-hormonal option matches the efficacy of estrogen, drugs like elinzanetant and fezolinetant represent important advances providing substantial symptom relief in many patients.
Study Strengths and Limitations
The OASIS-3 trial’s large size, rigorous design, and one-year duration lend strong credibility to findings. Secondary endpoints suggested improvements in sleep quality and overall well-being, though these were less extensively studied. No harmful effects on liver function or bone density were observed, addressing key safety concerns.
However, longer-term effects beyond one year remain to be fully evaluated, and while the drug shows promising tolerability, clinicians should monitor individual responses.
Public Health Implications
This new pill broadens treatment options for millions of women suffering menopause symptoms, particularly those unable or unwilling to use hormone therapy. By effectively controlling disruptive hot flashes and night sweats, it can improve daily functioning, work productivity, and mental health for many.
Healthcare providers should consider this evidence-based, non-hormonal option in menopause management, tailoring treatment to each woman’s medical profile and preferences.
Expert Perspectives
Dr. Sarah Huang, a menopause specialist not involved in the study, commented, “Elinzanetant’s targeted mechanism and strong trial results make it a game changer in menopause care. We now have a scientifically grounded non-hormonal choice that can help many women maintain comfort and quality of life through midlife transition.”
Practical Takeaways for Women
-
Elinzanetant offers a new daily pill option for reducing hot flashes and night sweats without hormones.
-
Women should consult healthcare providers to discuss benefits, risks, and personalized menopausal symptom management.
-
This option is particularly valuable for women who have contraindications for hormone therapy or prefer to avoid hormones.
-
While promising, ongoing monitoring and future research will clarify long-term safety and benefits.
Balanced View and Ongoing Research
While the new pill is a major step forward, hormone therapy remains the most effective treatment for many women. Additionally, behavioral therapies like cognitive behavioral therapy and lifestyle modifications can complement medical treatment.
Researchers continue to explore innovative therapies to address all aspects of menopause, including bone health, mood, and genitourinary symptoms, aiming for holistic care.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
